Atai Life Sciences N.V. (ATAI)
| Market Cap | 979.53M |
| Revenue (ttm) | 2.31M |
| Net Income (ttm) | -119.40M |
| Shares Out | 214.34M |
| EPS (ttm) | -0.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,918,415 |
| Open | 4.480 |
| Previous Close | 4.390 |
| Day's Range | 4.360 - 4.740 |
| 52-Week Range | 1.030 - 4.740 |
| Beta | 1.55 |
| Analysts | Strong Buy |
| Price Target | 13.33 (+191.69%) |
| Earnings Date | Aug 14, 2025 |
About ATAI
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with sc... [Read more]
Financial Performance
In 2024, Atai Life Sciences's revenue was $308,000, a decrease of -1.91% compared to the previous year's $314,000. Losses were -$149.27 million, 271.1% more than in 2023.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for ATAI stock is "Strong Buy." The 12-month stock price target is $13.33, which is an increase of 191.69% from the latest price.
News
Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus
Despite the phase 2b failure of inidascamine for CIAS, I maintain a Buy on Atai due to its diversified psychedelic pipeline. Beckley Psytech's BPL-003 drug for treatment-resistant depression showed st...
Why Is ATAI Life Sciences Stock Trading Lower On Monday?
Amid a surge in research targeting cognitive disorders, the pharmaceutical industry is witnessing a wave of pivotal trial results that could reshape schizophrenia treatment paradigms. As biotech firms...
ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.3% on Monday.
Atai Life Sciences schizophrenia drug fails to meet main goal in mid-stage trial
Atai Life Sciences and its partner Recognify Life Sciences said on Friday their experimental drug did not meet the main goal in a mid-stage trial for patients with cognitive impairment linked to schiz...
Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia
SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognify Life Sciences, a clinical-stage biotech company focused on developing treatments for cognitive impairment, today announced that its ran...
Atai: Critical Study Win Sets Up Double Approval Shot For Psychedelics In TRD
Atai Life Sciences' BPL-003 showed robust, rapid, and durable antidepressant effects in Phase 2b TRD data, spiking shares over 20%. BPL-003's short clinic time and strong efficacy could fit existing t...
Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data
Atai Life Sciences ATAI and Beckley Psytech Limited jointly announced topline results from the eight-week, quadruple-masked, dose-finding core stage of the Phase 2b trial of a single dose of BPL-003 (...
atai Life Sciences Announces $50 Million Private Placement Financing
Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1 Financi...
atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression
NEW YORK, and AMSTERDAM and OXFORD, United Kingdom, July 01, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company on a mission to develop hi...
atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies
NEW YORK and BERLIN and OXFORD, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to de...
atai Life Sciences to Participate in Upcoming Investor Conferences
NEW YORK and BERLIN, May 29, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective ment...
atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech's Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression
- Positive results show that a single dose of BPL-003, administered adjunctively to SSRIs, produced a rapid and durable antidepressant effect for up to three months after dosing
atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates
With clinical momentum across its pipeline, atai strengthens its position as a leader in potentially transformative psychedelic mental health treatments
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder
- In a Phase 1 study, EMP-01 (oral R-MDMA) demonstrated a unique, dose-dependent subjective effect profile that was generally found to be more similar to classical psychedelics than to racemic MDMA
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
- Elumina is a Phase 2, multicenter, double-blind, randomized, placebo-controlled, clinical trial to assess the efficacy, safety and tolerability of VLS-01 (buccal film DMT) in people suffering from t...
Atai: Following The Path That Spravato Laid And Moving Beyond It
Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds. Standing on the shoulders of Johnson & Johnson's Spravato.
atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference
NEW YORK and BERLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental h...
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
NEW YORK and BERLIN, Feb. 20, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of ment...
atai Life Sciences Announces Pricing of Public Offering of Common Shares
NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of ment...
atai Life Sciences Announces Proposed Public Offering of Common Shares
NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of ment...
Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst
Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients, showing a 50% abstinence in patients over a 12-week period. Release of results...
atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health
- Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer - Kevin Craig, M.D. promoted to Chief Medical Officer - Glenn Short, Ph.D. promoted to Chief Scientific Officer - Gerd Kochendoerfer...
IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG
MONTRÉAL, Oct. 02, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (the “Company” or “IntelGenx”), a leading drug delivery company focused on the development and manufacturing of pharmaceutical ...
atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
NEW YORK and BERLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...
Psychedelic Stock Deep Dive: Atai Life Sciences
After the FDA's rejection of Lykos Therapeutics' NDA for MDMA therapy, we take a more complete look at major psychedelic stocks. Atai Life Sciences is an early mover with a unique company structure an...